The COGNI-REHAB Trial is a single-site, phase O/I, randomized, double-blind, placebo-controlled study of human chorionic gonadotropin (hCG; choriogonadotropin alfa, Ovidrel®) in men with post-acute, moderate to severe traumatic brain injury (msTBI). Its objective is to assess the safety and efficacy of a 24-week regimen of Ovidrel (125 micrograms twice weekly) compared to placebo on treatment-emergent adverse events (TEAEs), cognitive and functional recovery, and circulating sex hormones.
This project aims to re-purpose a safe, well-tolerated, already-approved medication: human chorionic gonadotropin (hCG; choriogonadotropin alfa, Ovidrel®) for use in the post-acute rehabilitation of moderate to severe traumatic brain injury (msTBI). Ovidrel is currently FDA-approved for use in ovulation induction and Assisted Reproductive Technologies (ART). The rationale for using Ovidrel comes from a convergence of evidence indicating that hCG has neurodevelopmental and neuroregenerative properties, and from preclinical studies demonstrating that hCG reverses TBI-induced suppression of sex hormone production (i.e., reverses hypogonadism) and improves recovery of sensorimotor and spatial learning and memory in rodents following a focal injury to the medial prefrontal cortex. Recovery from a TBI is typically a very slow process because innate neuronal regeneration is a slow process; thus, Ovidrel (125 µg twice weekly) treatment will be evaluated over 24-weeks in patients that are 1-6 months post-TBI.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
50
Ovidrel, recombinant human chorionic gonadotropin, comes in a prefilled syringe for subcutaneous injection, is the investigational agent that will be used in this trial. Ovidrel® PreFilled Syringe is a sterile, liquid intended for subcutaneous (s.c.) injection. Each Ovidrel® PreFilled Syringe is filled with 0.515 mL containing 257.5 micrograms of choriogonadotropin alfa, 28.1 mg mannitol, 505 g 85% O-phosphoric acid, 103 g L-methionine, 51.5 g Poloxamer 188, Sodium Hydroxide (for pH adjustment), and Water for Injection to deliver 125 micrograms of choriogonadotropin alfa in 0.25 mL twice weekly. The pH of the solution is 6.5 to 7.5.
Prefilled syringe of 0.250 mL normal saline.
William S. Middleton Memorial Veterans Hospital, Madison, WI
Madison, Wisconsin, United States
Percent change in Treatment-Emergent Adverse Events
The frequency and type of individual TEAEs, discontinuations due to TEAEs, serious TEAEs, and clinically significant changes in laboratory test values.
Time frame: Baseline, 26 Weeks
Percent change in modified Functional Independence Measure (FIM)
The FIM is a standardized rating of motor and cognitive disability is commonly used to guide and track progress during rehabilitation, drilling down into level of assistance required for various daily tasks.
Time frame: Baseline, 24 Weeks
Glasgow Outcome Scale-Extended (GOSE)
The GOSE is a brief standardized tool developed for assessing TBI severity and recovery, offering a useful global indicator of disability severity.
Time frame: Baseline, 24 Weeks
Percent Change in Neuropsychiatric Inventory (NPI)
The NPI measures psychopathology in patients with neurological disorders, this tool allows brief screening of different conditions. When a screening item is positive, it follows up with more detail of symptom types, frequency, severity, and how distressing it is to caregivers. This makes for a very efficient and useful tool, providing a more comprehensive assessment of symptoms when they are present, and can be used to track recovery.
Time frame: Baseline, 24 Weeks
Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5)
This standardized self-rated scale detects presence and severity of PTSD symptoms and is used for monitoring during recovery. This is widely used in the veteran TBI literature as PTSD is frequently comorbid with TBI and can complicate recovery. This is a necessary complement to the NPI, which doesn't assess PTSD.
Time frame: Baseline, 24 Weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Percent change in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
RBANS is used in msTBI to assess cognitive impairment and track recovery in rehabilitation, this performance-based test generates a Total cognition score, which is made up of indices of Attention, Learning, Memory, Language, and Visuospatial skills. Each index can be broken down into two or more different aspects of the given cognitive domain. This allows for both global and more fine-grained analysis of cognitive impairment and recovery.
Time frame: Baseline, 24 Weeks
Percent change in Automated Neuropsychological Assessment Metrics Military (ANAM)
ANAM is used by the US military to assess cognitive function in service members for pre-deployment screening, post-injury monitoring, TBI detection and recovery. This test complements the RBANS by offering a measure of reaction time and more robust assessment of processing speed and executive functions.
Time frame: Baseline, 24 Weeks
Percent change in Trail Making Test (TMT)
TMT is a test of simple psychomotor speed and complex attention / executive control. It requires less manual dexterity than the RBANS and is less complicated by reaction time than the ANAM, so is useful in a mixed msTBI population as some participants may also have motor disability.
Time frame: Baseline, 24 Weeks
Columbia-Suicide Severity Rating Scale (C-SSRS)
The "Columbia Protocol" is a brief tool used by healthcare professionals to identify if a person is at risk for suicide.
Time frame: Baseline, 26 Weeks